Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 03, 2021 16:05 ET | Source: Zogenix, Inc

Zogenix to Participate in the BofA Securities SMID Cap 2H21 Ideas Conference

EMERYVILLE, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced...
July 22, 2021 08:00 ET | Source: Zogenix, Inc

Zogenix to Release Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5

EMERYVILLE, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that it will...
July 21, 2021 08:00 ET | Source: Zogenix, Inc

Zogenix Product FINTEPLA® (Fenfluramine) Recognized for Setting a New Standard for Dravet Syndrome Treatment Outcomes

In Epilepsy & Behavior editorial, authors write that FINTEPLA data demonstrate “unprecedented level of seizure control” for treated patients living with Dravet syndrome, a severe, debilitating...
July 14, 2021 16:01 ET | Source: Zogenix, Inc

VIP Siblings and www.vipsibling.com, New Resources to Support Brothers & Sisters of Those Living with Severe, Rare Epilepsies, Now Available from Zogenix and 10 Advocacy Groups

EMERYVILLE, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Zogenix, a global biopharmaceutical company developing rare disease therapies, and ten U.S. advocacy groups today announced the launch of VIP...
June 21, 2021 08:00 ET | Source: Zogenix, Inc

Zogenix to Participate in Two Upcoming Investor Conferences

EMERYVILLE, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that members...
May 11, 2021 16:01 ET | Source: Zogenix, Inc

Zogenix to Participate in the BofA Securities 2021 Healthcare Conference

EMERYVILLE, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J....
May 06, 2021 16:01 ET | Source: Zogenix, Inc

Zogenix Provides Corporate Update and Reports First Quarter 2021 Financial Results

Continued positive momentum for U.S. launch of FINTEPLA® (fenfluramine) oral solution in Dravet syndrome, with total net product sales of $12.3 million and total revenue of $13.7 million in the first...
April 27, 2021 08:00 ET | Source: Zogenix, Inc

Zogenix Launches Global Access Program for FINTEPLA® (Fenfluramine) Oral Solution

FINTEPLA is approved in the U.S. and European Union as an add-on therapy for the treatment of seizures associated with Dravet syndrome in patients aged two years and older.The new program supports...
April 22, 2021 08:01 ET | Source: Zogenix, Inc

Zogenix Presents New Data at Virtual AAN 2021 Showing Improved Executive Function in Lennox-Gastaut Syndrome (LGS) Patients Treated with FINTEPLA® (Fenfluramine) Oral Solution

LGS is one of the most challenging developmental and epileptic encephalopathies to manage because of high seizure frequency and significant neurodevelopmental impairment.More LGS study patients...
April 22, 2021 08:00 ET | Source: Zogenix, Inc

Zogenix to Release First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 6

EMERYVILLE, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its financial...